The new information brought by our work describing the role of NADPH oxidase activation during ADCC by PMN and its regulation by SIRPα might help to design new agents to enhance myeloid cell function in the treatment of cancer while limiting adverse effects on healthy cells. This evidence concerns the gene SIRPA and cancer.